Executive readout · one minute
Call research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
ADAPY
$0.03
+22.81%
ADAPY
· Adaptimmune Therapeutics PLC
$0.03
+0.01 (+22.81%)
At close · Aug 28
Going-concern doubt
— flagged Aug 13, 2025
Substantial doubt about the company's ability to continue as a going concern.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Aug 13, 2025
Market Cap
$44.53M
Shares
1.59B
All earnings calls
Earnings call · FY2024 Q2
Adaptimmune Therapeutics PLC (ADAPY) Q2 2024 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Revenue
$128.23M
+2399.6% YoY
Diluted EPS
$0.04
Net income
$69.52M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Aug 12, 2024 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 12, 2024 · complete as-filed document